Brain Health, Reimagined
At Gate Neurosciences, we believe there’s a better way to treat central nervous system (CNS) diseases. By overcoming the limitations of current and emerging treatments, we offer a new generation of safe, potent, and rapid acting-therapies for the nearly 1 billion people worldwide suffering from neuropsychiatric and cognitive disorders.
Directly Enhancing Synaptic Function
Directly Enhancing Synaptic Function
Synaptic dysfunction is the biological basis for a number of CNS disorders, including depression. Our next-generation therapeutic candidates are designed to restore healthy and balanced brain signaling by enhancing underlying synaptic function using a novel, direct mechanism that modulates the NMDA receptor without causing the dissociative effects seen in other emerging therapies.

Powered by Precision
Powered by Precision
Our precision development approach includes objective EEG biomarkers, targeted patient subpopulations, and robust translational modeling combined with clinical trial experience in thousands of patients to position our therapeutic candidates for long-term success.
CNS Is In Our DNA
Our team has devoted decades to researching CNS disease biology and improving the treatment of CNS disorders, giving us the deep expertise necessary for meaningful innovation.
Leadership
-
Michael G. McCully
President & CEO
-
Ronald M. Burch, M.D., Ph.D.
Chief Medical Officer
-
Anantha Shekhar, M.D., Ph.D.,
Chief Scientific Officer
Board of directors
-
Michael G. McCully
Director, CEO
-
Derek A. Small
Executive Chairman
-
Sarah J. Schlesinger, M.D.
Director
Investors and Key Shareholders
News and Events
Gate Neurosciences Announces Positive Topline Human EEG Biomarker Results Demonstrating Dose-Dependent Target Activation in Phase 1 Study of Apimostinel
Gate Neurosciences Takes on Depression with Event-Driven Pharmacology
Gate Neurosciences to Highlight New Biomarker Data & Host R&D Day at 2023 ASCP Annual Meeting
Contact Us
Headquarters
1210 Waterway Blvd
Indianapolis, IN 46202
United States